GNCA Genocea Biosciences Inc.

2.09
0  0%
Previous Close 2.09
Open 2.1
52 Week Low 1.1
52 Week High 5.75
Market Cap $107,917,687
Shares 51,635,257
Float 51,318,860
Enterprise Value $45,573,039
Volume 150,417
Av. Daily Volume 365,957
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
GEN-009
Various cancers
Phase 1/2
Phase 1/2
Phase 1/2 data presented at SITC November 2020.
GEN-011
Various tumors
Phase 1/2
Phase 1/2
Phase 1/2 trial has been initiated.
GEN-004
Universal vaccine candidate against pneumococcus
Phase 2
Phase 2
Topline data did not meet endpoints - September 2015

Latest News

  1. CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18th at 8:40 a.m. ET.

    A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 90 days following the presentation.

    About Genocea Biosciences, Inc.
    Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies…

    CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18th at 8:40 a.m. ET.

    A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 90 days following the presentation.

    About Genocea Biosciences, Inc.

    Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit www.genocea.com.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

    Investor Contact:

    Dan Ferry

    617-430-7576

    Primary Logo

    View Full Article Hide Full Article
  2. Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies

    GEN-011, a neoantigen-targeted peripheral T cell ("NPT") product, addresses several critical adoptive T cell therapy challenges

    ATLASTM-identified Inhibigens decrease anti-tumor T cell responses, cannot be overcome by powerful checkpoint blockade immunotherapy

    CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented four posters that collectively validate the company's unique and differentiated approach to identifying clinically meaningful immunotherapy…

    Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies

    GEN-011, a neoantigen-targeted peripheral T cell ("NPT") product, addresses several critical adoptive T cell therapy challenges

    ATLASTM-identified Inhibigens decrease anti-tumor T cell responses, cannot be overcome by powerful checkpoint blockade immunotherapy

    CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented four posters that collectively validate the company's unique and differentiated approach to identifying clinically meaningful immunotherapy targets at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting taking place virtually November 9th – 14th.

    GEN-009

    In follow up to data shared at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, the company shared expanded clinical and immunogenicity findings from Part B of its ongoing GEN-009 Phase 1/2a trial, which evaluates GEN-009, Genocea's neoantigen vaccine, in combination with PD-1 inhibitors in advanced cancers. Posters 390 and 413 outline the clinical and immune responses elicited by GEN-009 in 16 checkpoint inhibitor (CPI) therapy sensitive and resistant patients. Poster 413 was a highly scored abstract selected for a "Poster Walk."

    Of the nine CPI-sensitive patients, three patients experienced a novel reduction in tumor volume post-GEN-009 dosing and achieved independent RECIST responses after vaccination, including 2 PRs and 1 CR. Five additional CPI-sensitive patients have shown disease control post-vaccination for up to 11 months. Within the CPI-resistant population, five of seven patients appear to have stabilized disease lasting up to seven months. GEN-009 elicited strong anti-tumor immune responses with both CD4+ and CD8+ T cell responses observed at day 50 post-vaccination and with peak ex vivo responses occurring Day 92. Early data from two patients tested so far show a complete absence of circulating tumor DNA by day 50, which is consistent with a vaccine clinical effect. There was also emerging evidence of epitope spreading in patients who successfully responded to therapy. GEN-009 was safe and well tolerated.

    "We are highly encouraged by the response patterns observed in this clinical cohort, which are a novel signal that further support the possibility that GEN-009 administration can significantly decrease tumor burden in certain patients" said Thomas Davis, M.D., Chief Medical Officer of Genocea. "Augmenting the breadth of immune response against relevant cancer specific targets through GEN-009 can deepen CPI response in patients with advanced disease. We will continue to monitor these patients to measure the GEN-009 impact on longer-term disease stabilization. While we await these data, we do not intend to dose additional patients. We believe the cumulative GEN-009 data set establishes a differentiated clinical profile based on superior neoantigen selection and also provides a strong foundation for GEN-011, which also utilizes ATLAS selected targets to generate a potent cell therapy."

    Inhibigens

    One distinguishing feature of Genocea's proprietary ATLAS technology is its ability not only to identify the stimulatory neoantigens to include in GEN-009 and GEN-011, but also to reveal Inhibigens – peptides that elicit T cell responses with the capacity to compromise anti-tumor immunity. Poster 526 delves further into the biology of Inhibigen-specific responses and reveals important insights that add to the company's growing body of knowledge beyond data previously shared at the AACR Virtual Annual Meeting II. Findings in mice and humans confirmed the presence of Inhibigens in nearly every sample screened, and mouse data show the abrogation of anti-tumor activity in response to otherwise protective vaccines is associated with decreased CD4+ and CD8+ T cell, macrophage and dendritic cell infiltration into tumors. This outcome may be attributed to abolished cytokine activity in response to tumor-specific vaccine antigens. The data also show that vaccination with an Inhibigen renders CPI co-administration ineffective.

    "Our understanding of Inhibigens' mechanism of action and their translational relevance will be critical as we advance Genocea's vaccine and adoptive T cell therapy products through the clinic," said Jessica Baker Flechtner, Chief Scientific Officer of Genocea. "Immunotherapies targeting PD-1 and CTLA-4 have become standard of care across multiple cancer indications with remarkable yet variable effects. Learning more about Inhibigen biology may be critical to improving standard-of-care treatments for patients. We believe that Inhibigens must be identified and excluded from the rational design of immunotherapies, including GEN-011, the company's NPT product."

    GEN-011

    Poster 149 highlights important advantages of GEN-011 over TIL and TCR-T therapies. GEN-011 has been developed with 100% manufacturing success at clinical scale via PLANET™, a process designed to deliver billions of NPTs for every patient. The 16 PLANET runs conducted to date have confirmed GEN-011 comprises over 98% of highly functional, non-exhausted T cells with a mean neoantigen breadth of response nearing 90% of intended targets. In contrast, recent reported data from TIL products showed responses to less than 10% of intended neoantigens. GEN-011 NPTs have an unparalleled breadth of neoantigen coverage, targeting up to 30 relevant antigens. The drug product also avoids pro-tumor Inhibigens that may hinder clinical responses and the PLANET process does not require extra surgery or viable tumor.

    "I am pleased by the body of work shared today," said Chip Clark, President and Chief Executive Officer of Genocea. "Our proprietary ATLAS platform has played an integral role in the development of GEN-009 and GEN-011, and we remain eager to continue using ATLAS-based insights to identify both the right targets and Inhibigens to advance these programs in 2021 and beyond."

    About Genocea Biosciences, Inc.

    Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit www.genocea.com.

    Forward-Looking Statements

    This press release includes forward-looking statements, including statements related to the possibility that GEN-009 administration can significantly decrease tumor burden in certain patients and the use of ATLAS-based insights to potentially identify both the right targets and Inhibigens to advance programs in 2021 and beyond. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

    Investor Contact:

    Dan Ferry

    617-430-7576

    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor call with a live Q&A on Monday, November 9th at 8:30 a.m. EST to provide additional details on the clinical and immune response data from the remaining GEN-009 Part B patients to be shared at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) taking place virtually November 9th – 14th.

    Genocea's Chief Executive Officer Chip Clark, Chief Medical Officer Thomas Davis, M.D. and Chief Scientific Officer, Jessica Flechtner, will provide additional context around the following GEN-009 poster presentations:

    Abstract Number: 390

    CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor call with a live Q&A on Monday, November 9th at 8:30 a.m. EST to provide additional details on the clinical and immune response data from the remaining GEN-009 Part B patients to be shared at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) taking place virtually November 9th – 14th.

    Genocea's Chief Executive Officer Chip Clark, Chief Medical Officer Thomas Davis, M.D. and Chief Scientific Officer, Jessica Flechtner, will provide additional context around the following GEN-009 poster presentations:

    Abstract Number: 390

    Title: Emerging safety and activity data from GEN-009-101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 checkpoint inhibitors (CPI) in advanced solid tumors

    Abstract Number: 413

    Title: GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors

    Interested participants may access the conference call by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) and referring to conference ID number 13712664. To ask a question during the live Q&A, please submit your question to . For those who are unable to listen in during the event, a replay of the call will be available here.

    Genocea's GEN-009 posters (along with posters highlighting Inhibigen™ data and the neoantigen cell therapy GEN-011) will become available to registered attendees through the SITC virtual meeting platform at 8 a.m. EST on Monday, November 9th. Poster presentations with accompanying video will also be simultaneously posted to "Events and Presentations" tab of the investor relations section of the Genocea website.

    Webcast & Conference Call Information

    A live webcast of the investor call can also be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.

    About Genocea Biosciences, Inc.

    Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit www.genocea.com.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

    Investor Contact:

    Dan Ferry

    617-430-7576

    Primary Logo

    View Full Article Hide Full Article
  4. Initiated GEN-011 Phase1/2a clinical trial

    Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy

    Closed financing with net proceeds of $74.5 million

    Upcoming presentations at SITC 2020 Virtual Conference on GEN-009, InhibigensTM and GEN-011

    Conference call today at 8:30 a.m. EDT

    CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial results for the third quarter ended September 30, 2020.

    GEN-011 Phase 1/2a clinical trial initiation
    Genocea recently announced the…

    Initiated GEN-011 Phase1/2a clinical trial

    Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy

    Closed financing with net proceeds of $74.5 million

    Upcoming presentations at SITC 2020 Virtual Conference on GEN-009, InhibigensTM and GEN-011

    Conference call today at 8:30 a.m. EDT

    CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial results for the third quarter ended September 30, 2020.

    GEN-011 Phase 1/2a clinical trial initiation

    Genocea recently announced the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) Application for GEN-011, an adoptive neoantigen T cell therapy designed to improve upon the limitations of TIL and TCR therapies. The company initiated a Phase 1/2a clinical study of GEN-011 in patients who have failed standard-of-care checkpoint inhibitor therapy to evaluate safety, T cell proliferation and persistence as well as clinical activity. Genocea plans to enroll up to 24 patients across several tumor types in the trial.

    Scientific and clinical presentations: ESMO Congress, upcoming SITC meeting and conference call

    Genocea presented clinical response and immunogenicity data on the first five patients from Part B of the ongoing GEN-009 Phase 1/2a trial at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The incremental follow-up findings demonstrated tumor reductions or stable outcomes for all five patients, suggesting GEN-009 vaccination could be used in conjunction with CPI-based therapies to augment their effects. In addition, 100% of patients demonstrated immune responses to ATLAS™-identified neoantigens.

    Genocea will report additional clinical and immunogenicity data from the remaining GEN-009 Part B patients during the 2020 virtual Society for Immunotherapy of Cancer (SITC) annual meeting from November 9-14. The company will also provide a detailed introduction to GEN-011 and will share new insights on the utility of ATLAS-identified Inhibigens to inform future immunotherapy development.

    Genocea will host a conference call on Monday, November 9 at 8:30 a.m. EST to discuss the new GEN-009 clinical and immunogenicity data reported at SITC.

    Private placement

    In July, Genocea completed a private placement with $74.5 million in net proceeds. The proceeds will be used to fund continued development of GEN-009, GEN-011 and ATLAS.

    "In the third quarter, our team achieved important clinical, scientific and financial progress. We provided what we believe to be differentiated immunogenicity and efficacy data from an initial look at our GEN-009 Part B clinical trial and secured critical fresh capital", said Chip Clark, president and chief executive officer Genocea. "Using these proceeds to advance GEN-011 into the clinic and to further our investigation into ATLAS and its applications represents an exciting opportunity."

    Third Quarter 2020 Financial Results

    • Cash position: As of September 30, 2020, cash and cash equivalents were $87.6 million versus $40.1 million as of December 31, 2019.
    • Research and Development (R&D) expenses: R&D expenses were $7.5 million for the quarter ended September 30, 2020, compared to $6.8 million for the same period in 2019.
    • General and Administrative (G&A) expenses: G&A expenses were $3.6 million for the quarter ended September 30, 2020, compared to $2.8 million for the same period in 2019.
    • Net loss: Net loss was $4.6 million for the quarter ended September 30, 2020, compared to $7.5 million for the same period in 2019.

    Guidance

    Genocea expects that its existing cash and cash equivalents are sufficient to support its operations to mid-2022.

    Conference Call

    Genocea will host a conference call and webcast today at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

    About Genocea Biosciences, Inc.

    Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we are commencing a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

    Investor Contact:

    Dan Ferry

    617-430-7576



    (Tables to follow)



    GENOCEA BIOSCIENCES, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

    (In thousands)

      September 30, 2020 December 31, 2019
         
    Cash and cash equivalents $87,625  $40,127 
    Right of use assets 10,737  6,306 
    Other assets 7,836  6,178 
    Total assets $106,198  $52,611 
         
    Accounts payable and accrued expenses $6,351  $5,164 
    Deferred revenue 1,641   
    Debt, current and long-term 13,743  13,407 
    Warrant liabilities 53,237  2,486 
    Lease liabilities 11,021  6,512 
    Total liabilities 85,993  27,569 
    Stockholders' equity 20,205  25,042 
    Total liabilities and stockholders' equity $106,198  $52,611 





    GENOCEA BIOSCIENCES, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

    (In thousands, except per share data)

     Three Months Ended

    September 30,
     Nine Months Ended

    September 30,
     2020 2019 2020 2019
    License revenue$453  $  $1,359  $ 
            
    Operating expenses:       
    Research and development7,548  6,826  26,123  20,135 
    General and administrative3,644  2,758  10,511  8,992 
    Total operating expenses11,192  9,584  36,634  29,127 
    Loss from operations(10,739) (9,584) (35,275) (29,127)
    Other income (expense)6,184  2,052  6,546  (467)
    Net loss$(4,555) $(7,532) $(28,729) $(29,594)
            
    Net loss per share:       
    Basic$(0.08) $(0.28) $(0.76) $(1.62)
    Diluted$(0.26) $(0.28) $(1.01) $(1.62)
    Weighted-average number of shares used in computing net loss per share:       
    Basic55,492  26,681  37,657  18,297 
    Diluted61,130  26,681  39,550  18,297 

    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.

    Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations.

    A webcast replay will be available on the Genocea website beginning approximately…

    CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.

    Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5951388. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations.

    A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

    About Genocea Biosciences, Inc.

    Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we are commencing a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

    Investor Contact:

    Dan Ferry

    617-430-7576

     

    Primary Logo

    View Full Article Hide Full Article
View All Genocea Biosciences Inc. News